Wegovy pill fit better into one user's life after switching from injections.

A US patient who had used weekly compounded semaglutide injections switched to the FDA-approved daily Wegovy pill in January and reported about 8lb lost in the first month; the pill became available in US pharmacies on January 5 and prescriptions rose rapidly.

Colleen O'Connor, a US patient who had been using compounded weekly semaglutide injections, said she discarded a dose while travelling after finding her hotel room lacked a refrigerator. She had been on weekly injections since February 2025 and saw initial weight loss before reaching a plateau. In January she switched to the daily FDA-approved Wegovy pill and reported renewed progress. The pill became available in US pharmacies on January 5 and prescriptions rose quickly. Key facts: - O'Connor said she threw away a compounded weekly injection after it sat at room temperature during travel because refrigeration was unavailable. - She began weekly semaglutide injections in February 2025 and initially lost about 30lb before her weight loss plateaued. - The article reports she has lost roughly 40lb overall and is nearing a personal goal of 50–60lb. - She switched to the daily Wegovy pill in January and reported losing about 8lb in the first month after the change. - The oral formulation became available on January 5, and by January 23 weekly prescriptions exceeded 50,000 with more than 170,000 people taking the drug. - Both injectable and oral versions commonly affect the digestive system, and clinicians say longer-term real-world data on the pill remain limited. Summary: The article reports the patient experienced renewed weight-loss progress and fewer practical difficulties after switching to the Wegovy pill. Undetermined at this time.